Katherine E. Bowden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katherine E. Bowden has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alex de Voux
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA
1 shared publication - Allan Pillay
Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication - Anne M. Gaynor
Association of Public Health Laboratories, Silver Spring, MD
1 shared publication - Damien Danavall
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
1 shared publication - Ellen Neumeister Kersh
Georgia Public Health Laboratory, Georgia Department of Public Health
1 shared publication - Kai H. Chi
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA
1 shared publication
Latest Publications
- 1 June 2021
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 49 (1) , e26-e28
Detection of Lymphogranuloma Venereum–Associated Chlamydia trachomatis L2 Serovars in Remnant Rectal Specimens Collected from 7 US Public Health Laboratories
The frequency of lymphogranuloma venereum or invasive Chlamydia trachomatis infection with serovar L1, L2, or L3 is unknown in the United States. While no diagnostic test is commercially available, we used a laboratory-developed test and detected lymphogranuloma venereum–associated serovar L2 in 14% of 132 remnant C. trachomatis–positive rectal swabs.
- 1 June 2021
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 49 (1) , e26-e28
Detection of Lymphogranuloma Venereum–Associated Chlamydia trachomatis L2 Serovars in Remnant Rectal Specimens Collected from 7 US Public Health Laboratories
The frequency of lymphogranuloma venereum or invasive Chlamydia trachomatis infection with serovar L1, L2, or L3 is unknown in the United States. While no diagnostic test is commercially available, we used a laboratory-developed test and detected lymphogranuloma venereum–associated serovar L2 in 14% of 132 remnant C. trachomatis–positive rectal swabs.